The intratumoral injection of talimogene laherparepvec, an oncolytic virus engineered to enhance immune recognition of cancer, resulted in a high response rate in combination with anti−PD-1 therapy. SUMMARYHere we report a phase 1b clinical trial testing the impact of oncolytic virotherapy with talimogene laherparepvec on cytotoxic T-cell infiltration and therapeutic efficacy of the anti−PD-1 antibody pembrolizumab. Twenty-one patients with advanced melanoma were treated with talimogene laherparepvec followed by combination therapy with pembrolizumab. Therapy was generally well-tolerated, with fatigue, fevers, and chills as the most common adverse events.

Terms of useThis work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:• You may download this work for personal use only. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying this open access version DIAGNOSIS AND TREATMENT OF BASAL CELL CARCINOMA: EUROPEAN CONSENSUS-BASED INTERDISCIPLINARY GUIDELINES On behalf of the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC)

Mailings and social media posts of the International Dermoscopy Society were used to recruit targeted groups. The recruitment was focused on medical personell interested in the diagnosis of skin cancer. It is possible that recruitment of raters is influenced by self-selection bias and therefore biased towards the selection of motivated and skilled raters. Skill level was included as a covariate in the interaction experiments. Each rater had to perform multiple screening tests to ensure that the self-reported experience matched actual skills. Because of self selection bias, the generalisability of our results to a less motivated group of readers may be limited. Ethics oversightEthics review board of the Medical University of Vienna Note that full information on the approval of the study protocol must also be provided in the manuscript.